Henry Schein reports Q1 2026 results today with the Street conspicuously split — fresh target cuts from two analysts landed just this morning, less than 24 hours before the print.
The analyst picture is the clearest tension ahead of the release. UBS and Mizuho both trimmed targets on the morning of earnings day itself, with UBS moving to $85 from $87 and Mizuho to $82 from $88, while both kept Neutral ratings. That contrasts with a Citigroup initiation at Buy with a $100 target from mid-April, and Evercore ISI maintaining Outperform at $90 after cutting from $100 in early April. Morgan Stanley sits at Underweight with a $64 target — the starkest bear on the board. The mean consensus price target is $87.21, implying roughly 20% upside from Wednesday's close of $72.44, though that gap reflects the width of the debate rather than a clear directional read. The stock is down around 2% on the day and off 2% over the past month, suggesting the market has not been giving the benefit of the doubt lately.
The bull case centres on Henry Schein's entrenched position in the dental distribution market, a new CEO with M&A credentials, and the expectation that at least half of future operating income will eventually come from higher-growth, higher-margin software and specialty segments. Forward EPS estimates rank in the 92nd percentile for year-over-year growth, a signal that the sell-side still models meaningful earnings acceleration even as near-term targets slip. Bears point to competition risk, the complexity of integrating software services into a traditional distribution business, and lingering exposure to any shifts in healthcare legislation. The EV/EBITDA multiple of around 11.3x is not demanding for the sector, but the $2.95 billion net debt load and roughly 10 days-to-cover on short interest suggest the market wants tangible progress before re-rating the stock.
Short interest adds a layer of context rather than urgency. At 5.7% of the free float, it is meaningful but not extreme. The notable feature is the one-month trajectory: short positions have risen about 23% over the past 30 days, with the bulk of that build occurring in mid-April as macro uncertainty crested. That build has since started to fade modestly — shares short edged down roughly 0.6% in the latest session. Borrow conditions remain relaxed; cost to borrow is just 0.43% and availability is ample, so there is no squeeze dynamic in place. The ORTEX short score of 52.5 is middling — sitting near the 21st percentile of the short-score universe — consistent with positioning that is watchful rather than aggressive. Options lean the same direction: the put/call ratio is 0.07, well below its 20-day average of 0.10, meaning the options market is not hedging defensively into this print. Calls dominate the flow.
Institutional ownership adds an interesting footnote. KKR holds 13.3% of shares and trimmed slightly in its last reported period, while BlackRock added 279k shares through April. The insider picture over the past 90 days shows net selling across multiple executives in March, including the COO and Chief Strategy Officer — though the trades were modest in absolute dollar terms and carried low significance scores. The Q4 2025 print in late February produced a 1-day move of just -2.3% and a five-day decline of -3.3%, offering the only recent reaction data available.
The Q1 release is therefore less about the short-term positioning story and more about whether management can demonstrate that the pivot toward higher-margin software and specialty segments is gaining traction at a pace that justifies the valuation premium the Street is asked to assign.
See the live data behind this article on ORTEX.
Open HSIC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
